China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
Meta Expands AI Training With Employee Activity Tracking Tools 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
BRISBANE, Calif., March 09, 2017 -- KaloBios Pharmaceuticals, Inc. (OTC:KBIO), a biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases, announced that Cameron Durrant, MD, chairman and CEO, will present a company overview at the 29th Annual ROTH Conference.
The ROTH conference will be held March 12-15, 2017, at The Ritz-Carlton, Laguna Niguel, in Dana Point, Calif.
For more information on the conference, please visit www.roth.com/main/Page.aspx?PageID=7280.
About KaloBios Pharmaceuticals, Inc.
KaloBios Pharmaceuticals, Inc. (OTC:KBIO) is an emerging biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases through innovative and responsible business models. Lead compounds in the KaloBios portfolio are benznidazole for the potential treatment of Chagas disease in the U.S., and the proprietary monoclonal antibodies, lenzilumab and ifabotuzumab (formerly KB004), for the potential treatment of various solid and hematologic cancers such as CMML and potentially JMML. For more information, visit www.kalobios.com.
CONTACT: Investors: Mike Cole O: 949-259-4988 C: 949-444-1341 [email protected] Media: Lisa Guiterman O: 301-217-9353 C: 202-330-3431 [email protected]
